8 completed, 7 not yet recruiting, 5 recruiting, 2 active not recruiting. 16 Phase 1, 7 Not applicable, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 6, Not yet recruiting 4, Recruiting 4, Active not recruiting 2 |
| Not applicable | 7 | Not yet recruiting 3, Completed 2, Enrolling by invitation 2 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Healthy Participants Study: new trials by email Literature Review of Healthy Participants Study trials Research Report on Healthy Participants Study
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of QLS2312 Injection QLS2312 Injection, Placebo - Healthy Participants Study | Phase 1 | Not yet recruiting | Shanghai Qilu Pharmaceutical Research and Development Center LTD | 70 | 2026-11-11 | 2026-10-06 |
| Safety, Pharmacokinetics, and Pharmacodynamics of Continuous KL0011034 Infusion in Healthy Chinese Adults KL0011034 Injection, Propofol Injectable Emulsion - Healthy Participants Study, General Anesthesia | Phase 1 | Not yet recruiting | The Third Xiangya Hospital of Central South University | 30 | 2026-11-06 | 2026-09-25 |
| Neural Effects of Intravenous N,N-dimethyltryptamine (DMT) N,N-Dimethyltryptamine (15 mg), N,N-Dimethyltryptamine (17.5 mg) - Healthy Participants Study | Phase 1 | Not yet recruiting | Jon Dean | 20 | 2026-09-01 | 2026-07-09 |
| Phase I Clinical Study of ZL-65 Tablet in Healthy Adult Participants in China This group of participants take ZL-65 tablet, This group of participants take ZL-65 placebo tablet - Healthy Participants Study | Phase 1 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 108 | 2026-07-23 | 2026-08-11 |
| A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases CND319 - Healthy Participants Study, Rheumatoid Arthritis | Phase 1 | Recruiting | Candid Therapeutics | 105 | 2026-07-22 | 2026-10-21 |
| A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity ZP6590, solution for injection, Placebo, solution for injection - Healthy Participants Study, Overweight and Obese Adults | Early Phase 1 | Recruiting | Zealand Pharma | 88 | 2026-07-09 | 2026-08-13 |
| Healthy Participants Randomized, Double-blind, Placebo-controlled, Phase Ⅰ BY002, Placebo - Healthy Participants Study | Phase 1 | Recruiting | First Affiliated Hospital of Zhejiang University | 104 | 2026-06-01 | 2026-06-10 |
| A Phase 1 Study of Single-Dose BW-50218 in Healthy Chinese Participants BW-50218 Injection, Saline (0.9% NaCl) - Healthy Participants Study | Phase 1 | Active not recruiting | Shanghai Argo Biopharmaceutical Co., Ltd. | 24 | 2026-05-18 | 2026-09-23 |
| A Trial to Assess Safety, Tolerability, and Pharmacokinetics of AN01 Inhalation Powder in Healthy Participants AN01, Placebo - Healthy Volunteer, Healthy Participants Study | Phase 1 | Completed | AirNexis Therapeutics, Inc. | 25 | 2026-05-13 | 2026-08-17 |
| Study to Determine the Comparative Pharmacodynamics of Enoxaparin Sodium Biosimilar With That From Clexane Enoxaparin 40 Mg/0.4 mL Injectable Solution - Healthy Participants Study, The Focus of the Study is to Determine the Comparative Pharmacodynamic of Enoxaparin Sodium With That of Clexane in Healthy Human Participants | Phase 1 | Not yet recruiting | Egyptian International Pharmaceutical Industries Co | 26 | 2026-04-30 | 2026-04-08 |
| Study of BW-50218 in Healthy Participants BW-50218 Injection, Saline (0.9% NaCl) - Healthy Participants Study | Phase 1 | Active not recruiting | Shanghai Argo Biopharmaceutical Co., Ltd. | 60 | 2026-03-12 | 2026-09-03 |
| Safety and Pharmacokinetics of ALZ-507 in Healthy Elderly Adults ALZ-507, Placebo - Healthy Participants Study | Phase 1 | Recruiting | Alzheon Inc. | 84 | 2026-03-09 | 2026-09-17 |
| Positive Psychology - Based EMl for Enhancing Well-Being Ecological Momentary Intervention, Active Control - Healthy Participants Study | Not applicable | Not yet recruiting | The Hong Kong Polytechnic University | 354 | 2026-02-01 | 2026-02-12 |
| Assessment of the Relationship of Soft Contact Lens Fit and Power (Fit & Lens pOwer Soft lenSes) contact lens wear - Healthy Participants Study, Contact Lens Wear | Not applicable | Enrolling by invitation | Aston University | 38 | 2026-01-30 | 2026-01-21 |
| Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants cizutamig, Placebo - Healthy Participants Study | Phase 1 | Completed | Candid Therapeutics | 24 | 2025-12-04 | 2026-07-22 |
| Impact of Digital Oral Health Educational Program on a Group of Geriatrics Oral Health and Quality of Life Compared to Standard Oral Health Educational Program in Egypt elderly participant will receive digital educational oral health program., elderly participant will receive the standard oral health education in geriatric institution. - Oral Health Self-efficacy, Healthy Participants Study | Not applicable | Not yet recruiting | Cairo University | 40 | 2025-12-01 | 2025-07-28 |
| To Evaluate the Effect of Bacillus Subtilis Based Product in Gut Health and Immunomodulatory Effect in Healthy Adults. Probiotics (Bacillus Subtilis), Placebo - Healthy Participants Study | Not applicable | Enrolling by invitation | Bioagile Therapeutics Pvt. Ltd. | 46 | 2025-09-16 | 2026-01-30 |
| ACT-based EMI in College Students ACT-based ecological momentary intervention, Mood monitoring - Healthy Participants Study | Not applicable | Not yet recruiting | The Hong Kong Polytechnic University | 60 | 2025-04-15 | 2025-03-11 |
| Phase 1 Study of PRX019 in Healthy Adult Volunteers PRX019, Placebo - Healthy Participants Study | Phase 1 | Completed | Prothena Biosciences Ltd. | 50 | 2024-11-08 | 2026-05-14 |
| First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants KT-621, Placebo - Healthy Participants Study | Phase 1 | Completed | Kymera Therapeutics, Inc. | 118 | 2024-10-22 | 2025-10-02 |
Showing 20 of 24. Sign in to see all of them.
Arthritis, Rheumatoid (1) · Obesity (1) · Overweight (1) · Sjogren's Syndrome (1)
Arthritis (1) · Autoimmune Diseases (1) · Body Weight (1) · Connective Tissue Diseases (1) · Dry Eye Syndromes (1) · Eye Diseases (1) · Immune System Diseases (1) · Joint Diseases (1) · Lacrimal Apparatus Diseases (1) · Mouth Diseases (1) · Musculoskeletal Diseases (1) · Nutrition Disorders (1) · Nutritional and Metabolic Diseases (1) · Overnutrition (1) · Pathological Conditions, Signs and Symptoms (1)
Sodium Chloride (2) · Contact Lenses, Extended-Wear (1) · Control Groups (1) · Enoxaparin (1) · Injections (1) · N,N-Dimethyltryptamine (1) · Probiotics (1) · Solutions (1) · anifrolumab (1)
AstraZeneca (2) · Candid Therapeutics (2) · Shanghai Argo Biopharmaceutical Co., Ltd. (2) · The Hong Kong Polytechnic University (2) · AirNexis Therapeutics, Inc. (1) · Alzheon Inc. (1) · Aston University (1) · Bioagile Therapeutics Pvt. Ltd. (1) · Boung-hyoun Moon (1) · Cairo University (1) · Chengdu Zenitar Biomedical Technology Co., Ltd (1) · Egyptian International Pharmaceutical Industries Co (1) · First Affiliated Hospital of Zhejiang University (1) · Jon Dean (1) · Kymera Therapeutics, Inc. (1)
United States (6) · Australia (4) · China (4) · Germany (2) · United Kingdom (2) · Hong Kong (1) · India (1) · South Korea (1) · Switzerland (1)
Chad Swanson (1) · Jon Dean, PhD (1) · Parag Saudagar (1) · Ron Clijsen, PhD (1) · Yong Xiaolan, Doctor (1) · Yuqiong Li (1) · Yuqiong Li, MD (1)
2023 (1)